Investigating Liquid Biopsy to Predict Immunotherapy Success in Advanced Liver Cancer Hepatocellular Carcinoma
Led by University Hospital, Montpellier · Updated on 2025-07-10
60
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating advanced hepatocellular carcinoma HCC, a common and serious form of liver cancer, focusing on patients at stages B and C. This study aims to identify predictive biomarkers using a multi-omic liquid biopsy approach, which analyzes circulating tumor cells CTCs and immune profiles. It also examines whether there is a link between PD-L1 expression in tissue biopsies and in circulating tumor cells from blood samples. The goal is to better understand immunotherapy effectiveness in these patients.
Participants will provide 30mL blood samples at several time points, including before treatment starts and during routine care follow-ups. Blood is collected using specialized tubes for various analyses such as CTC detection, immune cell studies, and biobanking. The study uses a non-invasive liquid biopsy method to track tumor progression and immune response. There is no placebo or comparison treatment as this is an observational assessment alongside standard care.
During the study, participants will have blood drawn during regular visits, either in consultation or outpatient settings. Researchers will measure the percentage and number of PD-L1 positive CTCs at baseline, perform immune profiling over a 24-month follow-up, and analyze tumor control and survival outcomes. The study also involves tissue PD-L1 expression analysis at inclusion. Participants may be followed for up to two years to assess progression-free and overall survival while continuing their usual care.
CONDITIONS
Brief Title
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
Research Team
T
Thomas Bardol, M.D.
C
Catherine Guillemare
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosis of advanced hepatocellular carcinoma (HCC) at BCLC stages B or C
Indication for first-line PD-1 or PD-L1 immunotherapy without prior systemic therapy
Diagnosis established by imaging criteria or histological evidence
Patients able to provide oral consent
You will not qualify if you...
Previous systemic anti-tumor treatment including immunotherapy, chemotherapy, or targeted therapy
Personal history of cancer within the past 5 years
Personal history of systemic inflammatory diseases
Current immunosuppressive treatment or treatments that could affect immunity (e.g., anti-TNF)
Lack of affiliation or benefits from a Social Security system
Vulnerable persons unable to give informed consent
Pregnant or breastfeeding women
Inability to comply with follow-up due to transfer, poor motivation, or other significant health issues
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 24 months
Participants receive first-line PD-1 or PD-L1 immunotherapy and undergo blood sampling for liquid biopsy at baseline and during standard of care follow-up.
Blood samples collected at inclusion and during routine outpatient visits
Follow-up
Duration - Up to 24 months
Participants are monitored for tumor control, immune profiling, overall survival, and progression-free survival over 24 months.
Follow-up assessments during outpatient visits as part of routine care
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Evaluating 18F-FDGal PETCT and PETMRI for Diagnosis and Treatment Monitoring in Adults with Hepatocellular Carcinoma
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Phase 2 Study of 68Ga-PSMA-11 PET-Guided Radioligand Therapy with 177Lu-PSMA-617 in Adults with Metastatic Hepatocellular Carcinoma
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Open Label Study Evaluating BAY 3547926 Safety and Activity in Advanced Hepatocellular Carcinoma Patients
Comparing MRI, CT, and Two PET Scans 18F-FDGal and 18F-choline for Diagnosing Hepatocellular Carcinoma in Adults
Study on Using Pre-treatment Tumor Biopsies to Predict Response to PD-1PD-L1 Immunotherapy in Various Cancers
National Phase II Study of Proton Therapy for Hepatocellular Carcinoma in Adults
Aiming to Improve Treatment Safety and Outcomes by Reducing Liver Radiation Exposure
Phase I Study of Safety and Effects of GC001 Oncolytic Virus Injection in Adults with Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma.
Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer.